Trial Profile
A Phase I/II Study of Metronomic Cyclophosphamide and Oncolytic Poxvirus JX-594 in Patients With Advanced Hormone-receptor Positive and Triple Negative Breast Cancer and Advanced Soft Tissue Sarcoma (METROmaJX)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Cyclophosphamide (Primary) ; Pexastimogene devacirepvec (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms METROmaJX
- 27 Oct 2020 Treatment arms changed from 4 to 6. Avelumab is added in assigned interventions of treatment arms. New primary endpoints added.
- 21 Oct 2020 Planned number of patients changed from 118 to 197.
- 21 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 Nov 2024.